|
|
 Email  Print
|
Power3 Medical Products, Inc. OTCBB: PWRM
By: Publisher 12-16-09
Click link below to Receive:
The PWRM Research Report Prepared By CRWE Research.com
Company History
Originally formed as a medical device company, Power3 Medical Products, Inc. has since transitioned to an innovative holding company strategically positioned to acquire specialty healthcare and biotechnology assets. On May 18, 2004, Power3 purchased the assets and intellectual properties of ProteEx of The Woodlands, TX. The company was founded in 2000 by two seasoned medical biotechnology veterans with extensive protein expertise and a successful pioneering track record. The company has established a state-of-the-art proteomics laboratory and developed a proprietary process for the discovery, analysis, and identification of proteins. The most significant accomplishments to date are the development and proof-of-concept for a non-invasive breast cancer test and a blood test for neurodegenerative diseases. In addition, the Company is discovering proteins and protein patterns associated with many diseases including, but not limited to, prostate cancer, breast cancer, Alzheimer's disease, ALS (Lou Gehrig's disease), Parkinson's disease, and gastrointestinal disease.
Corporate Overview
Power3 Medical is a breakthrough proteomics company specializing in the identification of disease footprints in the areas of chemotherapeutic drug resistance and the early detection of breast cancer and neurological diseases. The research platform is centered on the study of proteomics, the science of protein interactions within living cells. With a combined 50+ years of proteomic experience, the Company has identified 334 protein biomarkers with the following potential medical applications:
 |
Breast Cancer |
|
Chemotherapeutic Drug Resistance |
|
Alzheimer's Disease |
|
Leukemia |
|
ALS (Lou Gehrig's Disease) |
|
Gastrointestinal Disease |
|
Parkinson's Disease |
|
Metabolic Syndrome |
Intellectual Property
Power3 pursues an aggressive intellectual property strategy to protect its inventions and discoveries made on its own and with its collaborators. Power3 works with key physician scientists at major medical research and treatment centers. With access to decisive human clinical samples and superior trade secret proteomic methodologies, the Company provides solutions to pressing challenges in diagnosis and treatment of patients and has concluded research agreements, technology license agreements, and filed provisional and utility patents. Power3 is also adding additional layers of research and license agreements, patent filings, and trade secrets, as its technology and product portfolio develops, to cover:
|
|
Processes - The manner in which the discoveries are made and tests developed |
|
|
Discoveries - Protein disease footprints, |
|
|
Products - Early detection tests, Biomarkers, and Drug Targets |
The intellectual property that Power3 has and continues to pursue today covers the product areas of breast cancer, neurodegenerative diseases, and drug resistance as depicted below:
Breast Cancer
Power3's early indication breast cancer NAF protein footprint test. More than 120 identified NAF protein biomarkers and drug targets for early indication and treatment of breast cancer NAF footprints for individualized therapy.
Neurodegenerative Diseases - ALS (Lou Gehrig's Disease), Alzheimer's Disease, Parkinson's Disease, Other Neurological Disorders
Power3's blood serum test for distinguishing between the neurodegenerative diseases
Blood serum biomarkers and drug targets for neurodegenerative disease
Resistance to Chemotherapy
Power3's test for prediction of response to drug therapy in cancer. Biomarkers and drug targets for treatment and monitoring of drug resistance
Management Team
Power3 Medical's Chief Executive Officer
Helen R. Park, CEO, Board of Directors, Power3 Medical Products, Inc. (09, 2009-present) is a serial entrepreneur, with 40 plus years in Science and Bio Technology business management. She founded Advanced Bio/Chem in 2000, and served as Chief Executive Officer and Chairman of the Board, through June 2004. Ms. Park is founder and CEO of Bronco Technology Inc., a contracting and consulting firm for bio-technology companies. Ms. Park has served as president and on various professional boards. She has an M.S. in Biochemistry from Baylor College of Medicine.
John Ginzler, B.S., MBA., Chief Financial Officer
On April 29, 2009, Mr. John P. Ginzler was named Chief Financial Officer of Power 3 Medical Products, Inc. Mr. Ginzler brings nearly 20 years of experience in the medical industry to Power 3. Previously, Mr. Ginzler served as Vice President, Finance of Critical Care Systems, Inc. since 2006. Prior to 2006, Mr. Ginzler served as Director of Accounting for Critical Care Systems. Mr. Ginzler has an MBA in Entrepreneurship, Cum Laude, from Babson College and a BS in Accounting, Summa Cum Laude, from Northeastern University.
Ira L. Goldknopf, Ph.D., Director, Chief Scientific Officer
Dr. Goldknopf has over 30 years of proteomic experience. He is a well recognized pioneer and leader in Proteomics, having produced, the first isolation, identification and sequencing of a new protein spot on a 2D gel. He also discovered ubiquitin conjugation of proteins, which laid the groundwork for the 2000 Lasker award. He was cofounder of ProteEx in 2000 and prior to that was founding CEO of UbiquiTex Technologies, and cofounder and VP of R&D of FlowGenix Corporation. His experience also includes Manager GMP, QC/QA, and analytical operations, GAF/ISP and Triplex Pharmaceuticals. He spent 10 years on the faculty of Baylor College of Medicine and a sabbatical year at the Medical Nobel Institute, Karolinska Institute, Stockholm, Sweden. He is the author of more than 70 publications and also serves on the Scientific Advisory Board of the Company.
For More Information. Please Visit. Power3 Medical Products, Inc.
|
|
|
|
| |
 |
|
| Discover Opportunities With Us ! |
 
|
| |
|
Digg
Del.icio.us
Reddit
Slashdot
Technorati
Newsvine
StumbleUpon
Google
Yahoo!
